Literature DB >> 18332454

The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.

Hoon Young Choi1, Dong Ki Kim, Tae Hee Lee, Sung Jin Moon, Seung Hyeok Han, Jung Eun Lee, Beom Seok Kim, Hyeong Cheon Park, Kyu Hun Choi, Sung Kyu Ha, Dae-Suk Han, Ho Yung Lee.   

Abstract

BACKGROUND: Long-term peritoneal dialysis (PD) is associated with the development of various structural and functional changes to the peritoneal membrane when bioincompatible conventional peritoneal dialysis fluids (PDFs) are used. In this study, we looked at patients that were treated with conventional PDFs and then changed to novel biocompatible PDFs with a neutral pH and a low concentration of glucose degradation products (GDPs) to investigate whether this change could result in the arrest or reversal of peritoneal membrane deterioration.
METHODS: In an open label, randomized prospective trial, the clinical effects of conventional PDFs and biocompatible PDFs with neutral pH and very low concentration of GDPs were compared in 104 patients equally divided between both study PDFs. Blood and effluent dialysate samples, peritoneal equilibration tests, and adequacy evaluation were undertaken at baseline, 4, 8, and 12 months. The target variables were the ratio of dialysate-to-plasma (D/P) creatinine, peritoneal ultrafiltration, residual renal function, dialysis adequacy indices, and effluent cancer antigen 125 (CA125).
RESULTS: D/P creatinine values were not different in the two groups. Peritoneal ultrafiltration was significantly higher in the low-GDP PDF group than in the conventional PDF group at all follow-up times (4 months: 9.1 +/- 4.3 vs 6.0 +/- 3.0; 8 months: 8.3 +/- 3.4 vs 6.0 +/- 3.0; 12 months: 8.9 +/- 3.3 vs 6.1 +/- 3.3 mL/g dextrose/day; p < 0.05). Peritoneal Kt/V urea values and total weekly Kt/V urea values at 4 months were significantly higher in the low-GDP PDF group than in the conventional PDF group. Residual renal function was not statistically significant. Effluent CA125 levels were significantly higher in the low-GDP PDF group at all follow-up visits (4 months: 37.8 +/- 20.8 vs 22.0 +/- 9.5; 8 months: 41.2 +/- 20.3 vs 25.9 +/- 11.3; 12 months: 40.4 +/- 21.4 vs 28.6 +/- 13.0 U/mL; p < 0.05). Among anuric patients, peritoneal ultrafiltration at 4, 8, and 12 months, total weekly Kt/V at 4 and 8 months, and CA125 levels at all follow-up visits were significantly higher in patients treated with low-GDP PDF than those treated with conventional PDF. However, among anuric patients, D/P creatinine showed no significant differences between the low-GDP PDF group and the conventional PDF group.
CONCLUSION: The use of biocompatible PDFs with neutral pH and low GDP concentration can contribute to improvement of peritoneal ultrafiltration and peritoneal effluent CA125 level, an indicator of peritoneal membrane integrity in PD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332454

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  28 in total

1.  Trials (and tribulations) of biocompatible peritoneal dialysis fluids.

Authors:  David W Johnson; Yeoungjee Cho; Fiona G Brown
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

2.  Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report.

Authors:  Y Kamijo; H Iida; K Saito; R Furutera; Y Ishibashi
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

3.  Normal peritoneal histology after ten years of peritoneal dialysis in a contemporary Japanese patient.

Authors:  M Tsukamoto; Y Ishibashi; Y Takazawa; Y Komemushi; H Kume
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

Review 4.  Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.

Authors:  Seychelle Yohanna; Ali M A Alkatheeri; Scott K Brimble; Brendan McCormick; Arthur Iansavitchous; Peter G Blake; Arsh K Jain
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 8.237

5.  Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael Suranyi; Seng H Tan; David Voss
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

6.  Balance about balANZ.

Authors:  Peter G Blake
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

7.  Buffer-dependent regulation of aquaporin-1 expression and function in human peritoneal mesothelial cells.

Authors:  Yihui Zhai; Jacek Bloch; Meike Hömme; Julia Schaefer; Thilo Hackert; Bärbel Philippin; Vedat Schwenger; Franz Schaefer; Claus P Schmitt
Journal:  Pediatr Nephrol       Date:  2012-03-01       Impact factor: 3.714

Review 8.  Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.

Authors:  Eun-Young Seo; Sook Hee An; Jang-Hee Cho; Hae Sun Suh; Sun-Hee Park; Hyesun Gwak; Yong-Lim Kim; Hunjoo Ha
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

Review 9.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

10.  Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry.

Authors:  Masashi Mizuno; Yasuhiko Ito; Yasuhiro Suzuki; Fumiko Sakata; Yosuke Saka; Takeyuki Hiramatsu; Hirofumi Tamai; Makoto Mizutani; Tomohiko Naruse; Norimi Ohashi; Hirotake Kasuga; Hideaki Shimizu; Hisashi Kurata; Kei Kurata; Satoshi Suzuki; Satoko Kido; Yoshikazu Tsuruta; Teppei Matsuoka; Masanobu Horie; Shoichi Maruyama; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2016-03-07       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.